deltatrials
Unknown PHASE3 INTERVENTIONAL 2-arm NCT04657133

Remote Ischemic Conditioning for the Treatment of Intracerebral Hemorrhage (RICH-2)

The Safety and Efficacy of Remote Ischemic Conditioning for the Treatment of Intracerebral Hemorrhage: A Multicenter, Randomized, Controlled Study

Sponsor: Capital Medical University

Updated 7 times since 2021 Last updated: Jul 16, 2022 Started: Apr 22, 2021 Primary completion: Dec 31, 2022 Completion: Jun 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04657133, this PHASE3 trial focuses on Acute Stroke and Intracerebral Hemorrhage and remains ongoing. Sponsored by Capital Medical University, it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotNot Yet Recruiting~Feb 2021 – ~Jun 2021 · 4 months · monthly snapshotNot Yet Recruiting~Jun 2021 – ~Sep 2022 · 15 months · monthly snapshotRecruiting~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotRecruiting~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshotRecruiting~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

7 versions recorded
  1. Sep 2024 — Present [monthly]

    Unknown PHASE3

  2. Aug 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: RecruitingUnknown

  3. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE3

  4. Sep 2022 — Jul 2024 [monthly]

    Recruiting PHASE3

  5. Jun 2021 — Sep 2022 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

Show 2 earlier versions
  1. Feb 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE3

  2. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Capital Medical University
Data source: Capital Medical University

For direct contact, visit the study record on ClinicalTrials.gov .